… Eligible individuals included all patients infected with HCV genotype 2 and genotype 3 who
initiated VA-prescribed DCV + SOF ± RBV or VEL/SOF ± RBV by the 31st March 2017 with …

… We performed a phase 2 trial of 204 patients with genotype 3 HCV infection and …
sofosbuvir and velpatasvir for 12 weeks (n = 101) or sofosbuvir and velpatasvir plus ribavirin …

… In conclusion, sofosbuvir-velpatasvir plus GS-9857 is a safe and effective treatment in
patients with HCV genotypes 2, 3, 4, and 6, with and without compensated cirrhosis. High SVR …

… of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using
a … POLARIS-3, which enrolled patients infected with HCV genotype 3 who had cirrhosis, …

… GT3 infection is associated with higher rates of liver steatosis, more rapid fibrosis … compared
to infection with other HCV genotypes.4-6 Historically, HCV GT3 infection was considered …

… of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the
NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus genotype 1 infection. …

… on global disease prevalence, especially in regions with high genotype diversity where
HCV genotyping and fibrosis staging are not part of routine medical care for HCV infection. …

… HCV genotype 3 infection and cirrhosis, ribavirin must be added. In patients with HCV
genotype 2 or 3 infection who had treatment failure with the use of sofosbuvir plus ribavirin with or …

… A total of 95 patients with chronic hepatitis C due to HCV genotype 1 and 2 infection who
underwent DAA treatment with the 12-week SOF/VEL regimen in our network of hospitals …

… limited by the small number of patients we enrolled with cirrhosis as well as HCV genotypes
1b, 2, 3, and 4, as well as the fact that no patients with HCV genotype 5 or 6 were enrolled. …